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Abstract: Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human
chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC)
patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p
and miR-367-3p and clinical features in metastatic TGCC. Methods: relative levels of miR-371a-3p,
miR-373-3p and miR-367-3p were evaluated in serum of metastatic TGCC patients. A prospectively
included and a retrospectively selected cohort were studied (total patient number = 109). Blood
samples were drawn at start of chemotherapy and during follow-up. Serum microRNA (miR)
levels were determined using the ampTSmiR test. Results: at start of chemotherapy, miR-371a-3p,
miR-373-3p and miR-367-3p levels were positively correlated to LDH. The median level of these miRs
was higher in patients who developed a relapse after complete biochemical remission (n = 34) than
in those who had complete durable remission (n = 60). Higher levels of miR-367-3p were found in
patients with refractory disease (n = 15) compared to those who had complete response. miR levels
decreased during the first week of chemotherapy in patients with complete response and stayed
below threshold after one year of treatment. Conclusion: high miR levels at start of chemotherapy
are associated with worse clinical outcome and can assist in early diagnosing of relapses.
Keywords: testicular germ cell cancer; microRNA; serum biomarkers; β-HCG; AFP; LDH
1. Introduction
Testicular germ cell cancer (TGCC) is rare, but the most common malignancy among young
Caucasian men. Even in case of disseminated disease the prognosis is good with cisplatin-based
chemotherapy. The tumor markers LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG
(human chorionic gonadotropin) produced by some of the cancer cells and measurable in serum
contribute to establish the diagnosis, with LDH being the less specific marker. These markers are also
used for risk stratification and follow-up of patients with metastatic disease, making them a highly
valuable tool for oncologists in daily practice. Nevertheless, overall only ~60% of TGCC patients have
elevated markers during the course of their disease [1]. The proportion of patients with elevated tumor
markers varies depending on the histological subtype. Around 90% of non-seminoma tumors will be
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positive for AFP orβ-HCG and up to 30% of seminomas will be positive forβ-HCG [2]. LDH is elevated
in 40–60% of patients regardless of the histological tumor type [3]. Prognosis-based staging of the
international germ cell cancer collaborative group (IGCCCG) guide oncologists in deciding treatment
for TGCC patients with metastatic disease [2,4]. Notwithstanding the good prognosis of this patient
group, ~20% of patients in the intermediate and 30% in poor risk groups, respectively, will die from the
disease [5,6]. It is crucial to investigate biomarkers that will help identifying patients who will develop
refractory disease or have a higher chance of a tumor relapse after an initial complete remission.
Tumor-derived products can be isolated from blood, with circulating DNA or RNA, exosomes
and circulating tumor cells (CTCs) recently being studied in relation to diagnosis and progression
of cancer patients [7]. Small non-coding RNAs, also known as microRNAs (miRs), are frequently
dysregulated in cancer cells and an oncogenic role of the miR-371 cluster has been described [8].
Specifically, miR-371a-3p and miR-373-3p, both members of the miR-371 cluster, as well as the
pluripotency-associated miR-367-3p have been studied in TGCC [9]. These reports have shown the
potential utility of the aforementioned miRs as novel biomarkers for diagnosis and follow-up of TGCC
patients after initial treatment [10–15]. The potential clinical value of the levels of these miRs in blood
lie in predicting the presence of viable disease [16], or detecting relapses [17] after chemotherapy for
TGCC has been recently described [18,19]. Nonetheless, these studies lack sufficient numbers of poor
outcome patients to evaluate the relationship between these miR levels and response to chemotherapy.
In addition, the kinetics of these miRs in relation to chemotherapy treatment have not been studied in
detail so far.
Therefore, the objectives of this study were to evaluate the potential use of circulating miR-371a-3p,
miR-373-3p and miR-367-3p levels to predict relapse or refractory disease in TGCC patients as well as
their accuracy at detecting relapses during follow-up after chemotherapy compared to the classical
tumor markers. An additional objective was to evaluate the kinetics of the miRs within the first week
after start of chemotherapy in patients with metastatic disease was evaluated. Blood samples were
collected from metastatic TGCC patients at start of chemotherapy and during treatment and follow-up
to assess the levels of miR-371a-3p, miR-373-3p and miR-367-3p using a serum based microRNA
detection assay (ampTSmiR test) and correlate these to clinical features.
2. Methods
2.1. Patients
Two different TGCC patient cohorts with metastatic disease (stages II to IV, according to the Royal
Marsden Hospital staging system [20]) were analyzed for this study: a prospectively included cohort
was used as a reference group (cohort 1) and a retrospectively selected and constructed cohort of
patients with unfavorable outcome (cohort 2). Ethical code number: UMCG2016/041, date of approval:
April 12, 2006. All participants gave written informed consent. Patients in cohort 1 received three
or four BEP courses (etoposide 100 mg/m2, days 1–5, cisplatin 20 mg/m2, days 1–5, with/without
bleomycin 30 USP, days 2, 8, 15) every three weeks. During the first six days of every course,
patients were hydrated with 4L saline per 24h. Serum samples of cohort 1 were taken before start of
chemotherapy (week 0) and during chemotherapy treatment at week 1, 3, 6, 8 and after ~3–6 months
and ~1y of start of chemotherapy. Cohort 1 was previously described [21]. This study investigated
BEP-chemotherapy-induced vascular activation and metabolic changes in metastatic TGCC patients
after first-line BEP chemotherapy. The majority of patients in cohort 2 also received three or four
BEP courses every three weeks as described above, although several received other platinum based
chemotherapy regimens. Patients treated at the UMCG, between February 1998 and October 2013,
were included. Patients in cohort 2 were selected from the UMCG local data-biobank of testicular
cancer patients upon the occurrence of relapse after first line chemotherapy for metastatic disease or
refractory disease during initial chemotherapy. In both cohorts, miR levels were associated with stage,
IGCCCG risk group, tumor type, classical tumor markers and clinical outcome.
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All serum samples were collected between February 1998 and February 2015, and stored after
primary handling at −20 ◦C. In total, serum samples of 109 patients with a median age of 31 years
(range 16–78 years) were included. miR levels of TGCC patients were compared with 104 sera of male
healthy donors, as described previously [10]. The normal control serum samples were obtained from
Sanquin (Amsterdam, The Netherlands).
2.2. Measurement of miR Levels by ampTSmiR Test
The miR purification, quantitative real-time PCR (RT-qPCR) and quality control were as described
earlier [10,11]. The miRs were isolated from 50 µL serum using target specific anti-miR magnetic beads
as described before [10,17,18]. A MagMaxTM Express-96 robot was used with TaqMan® microRNA
ABC Purification Kits (panel A, Thermo Fisher Scientific, Bleiswijk, The Netherlands). The following
TaqMan assays were used for cDNA generation and miR level quantification: hsa-miR-371a-3p (catalog
ID 002124); hsa-miR-373-3p (catalog ID 000561); hsa-miR-367-3p (catalog ID 000555); ath-miR-159a
(catalog ID 000338) and hsa-miR-30b-5p (catalog ID 000602) (Thermo Fisher Scientific). A TaqMan
MicroRNA RT KIT (Thermo Fisher Scientific) was used to reverse transcribe specifically targeted
purified miR (5 µL in elution buffer) into miR specific cDNA. Subsequently, a 13 cycle pre-amplification
step was performed using 2× TaqMan Preamp Master mix (4488593, detailed protocol by supplier
Thermo Fisher Scientific) and 20× TaqMan MicroRNA Assays. Thermal-cycling conditions: 95 ◦C for
10 min., next 13 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. miRNA levels were determined on a
TaqMan 7500 Real-Time PCR system in 1.5 µL of cDNA (Thermo Fisher Scientific).
2.3. Quality Control
A non-human miR spike-in ath-miR-159a was added for quality control of miR isolation and
cDNA generation and was used to correct for input. All sera were visually inspected and miR-451
was used to control for hemolysis, no samples were discarded from analysis. No samples had to be
excluded due to poor miR recovery. For normalization the mean levels of the endogenous reference
miR (miR-30b-5p) was used as described before [10,11,16]. In each cDNA synthesis experiment, a
dilution series of purified miR of the TCam-2 seminoma cell line was included for quality control and
qPCR efficiency and interplate calibration. As negative control (no template control), elution buffer
was added instead of purified miR.
2.4. Evaluation
The target miR level per sample was determined according to the delta Ct method. Relative miR
levels are depicted as 2∧(−delta Ct (miR of interest minus reference miR) × 104. A cutoff value of ≥2.0
time of the highest level observed in the healthy donor group was used to set a threshold as described
earlier [11]. This threshold was used to select patients for the kinetics analysis.
2.5. Statistical Analysis
Data are presented as median and range. For comparison between groups the Mann-Whitney U
test was applied. To study the correlation between tumor markers and miR relative levels, Spearman
correlation coefficient was used. To test significant differences in miR levels after start of chemotherapy,
repeated measures ANOVA was used. Two-sided p-values < 0.05 were considered significant. Statistical
analyses were performed in SPSS Statistics 22.0 (IBM SPSS Inc, Armonk, NY USA) and GraphPad
Prism 7.0 (GraphPad Inc, San Diego, CA, USA).
3. Results
3.1. Patients
This study used two different cohorts, and analysis was performed in two steps (Figure 1). Cohort 1
(prospectively included) was used as a reference group since it stands as a representative sample
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of metastatic TGCC with the advantage of having a fixed sampling schedule. Because of the good
prognosis of TGCC, cohort 1 lacked enough relapse and refractory disease cases. Therefore, cohort
2 (retrospectively selected) was added to this analysis to enrich for cases with unfavorable outcome.
Cohort 2 did not have a fixed sampling schedule for each patient besides the standard follow-up for
metastatic TGCC.
Cohort 1 consisted of 67 patients who were prospectively included. Eligibility criteria were
diagnosis of disseminated TGCC and BEP chemotherapy as first line treatment. Characteristics are
described in Table 1. The majority was stratified in the good risk group (83.6%) according to the
IGCCCG classification [4], and only 14.9% and 1.5% belonged to the intermediate and poor risk groups,
respectively. In total, six patients had a relapse and one had refractory disease.
Forty-two patients were retrospectively included in cohort 2. Eligibility criteria were diagnosis
of disseminated TGCC and presence of relapse after completion of chemotherapy or refractory
disease (defined as an increase in marker level during or at completion of first line chemotherapy).
Characteristics are shown in Table 1. At start of chemotherapy, 11 patients were classified in the good
(26.2%), 15 in the intermediate (35.7%) and 16 in the poor IGCCCG risk group (38.1%). Twenty-eight
patients (66.7%) had a relapse after an initial good biochemical response on chemotherapy and 14
patients had refractory disease on chemotherapy (33.3%).
Table 1. Clinical characteristics of cohorts 1 and 2.
Variable Number (%)
All Patients Cohort 167 (100%)
Cohort 2
42 (100%)
Tumor type (histology)
-Non seminoma 54 (80.3) 31 (73.8)
Embryonal carcinoma $ 44 19
Choriocarcinoma 6 9
Yolk sac 23 17
Teratoma 26 25
Seminoma 30 17
-Pure Seminoma 13 (19.7) 10 (23.8)
-Extragonadal 1 (2.4)
IGCCCG Risk Group
-Good 56 (83.6) 11 (26.2)
-Intermediate 10 (14.9) 15 (35.7)
-Poor 1 (1.5) 16 (38.1)
Response to Chemotherapy
-Durable complete response (NED) 60 (89.5) -
-Relapse after complete response (NED) 6 (9) 28 (66.7)
-Refractory disease 1 (1.5) 14 (33.3)
Stage (Metastatic Disease)
-II 54 (80.6) 12 (28.6)
-III 6 (9) 6 (14.3)
-IV 7 (10.4) 24 (57.1)
RPLND [Post Chemotherapy]
-Yes 32 (47.8) 16 (38.1)
Necrosis/fibrosis 11 5
Teratoma 20 8
Vital carcinoma 1 3
-No 35 (52.2) 26 (61.8)
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Table 1. Cont.
Variable Number (%)
All Patients Cohort 167 (100%)
Cohort 2
42 (100%)
β-HCG Measurements 61 (91) 41 (98)
-Positive 33 (54) 31 (76)
-Negative 28 (46) 10 (24)
AFP Measurements 62 (93) 42 (100)
-Positive 34 (55) 27 (64)
-Negative 28 (45) 15 (36)
LDH Measurements 60 (90) 41 (98)
-Positive 19 (32) 32 (78)
-Negative 41 (68) 9 (22)
IGCCCG: international germ cell cancer collaborative group; RPLND: retroperitoneal lymph node dissection.
β-HCG (human chorionic gonadotropin), AFP (alpha-fetoprotein) and LDH (lactate dehydrogenase). $ Different
histological components of non-seminoma in removed affected testicle. NED (No evidence of disease).
Figure 1. Schematic view of cohort 1, as described before (see Methods) and cohort 2 and the
analyses performed.
3.2. Association between miR Levels, Tumor Markers and IGCCCG Risk Groups in Cohort 1
Serum levels of LDH, AFP and β-HCG were compared with levels of miR-371a-3p, miR-373-3p
and miR-367-3p before start of chemotherapy. LDH levels had a positive correlation with levels of all
three miRs (miR-371a-3p, p ≤ 0.001; miR-373-3p, p ≤ 0.001; miR-367-3p, p = 0.005) (Supplementary
Table S1). β-HCG positively correlated with miR-371a-3p only (p = 0.045), whereas no correlation was
found between AFP and any of the analyzed miR levels (Supplementary Table S1).
Analysis of the miR levels before start of chemotherapy and IGCCCG risk stratification showed
that median miR-371a-3p levels were higher in patients from intermediate and poor risk groups
compared to patients belonging to the good risk group (p = 0.041) (Supplementary Figure S1A–C,
Supplementary Table S2).
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3.3. Association between miR Levels, Classical Tumor Markers and Clinical Features in
Cohort 1 and 2 Combined
Analysis of both cohorts combined (Figure 1) showed a positive correlation between LDH and
miR-371a-3p, miR-373-3p and miR-367-3p (all p≤ 0.001) (Figure 2A–C, Supplementary Table S3). β-HCG
was positively correlated with miR-371a-3p (r = 0.295; p = 0.003) and miR-373-3p (r = 0.263; p = 0.007)
but not miR-367-3p (r = 0.143; p = 0.151) levels (Supplementary Table S3). AFP was positively correlated
with miR-367-3p only (r = 0.194; p = 0.049) (Supplementary Table S3). The miR levels were evaluated
comparing tumor histology: median levels of miR-371a-3p (p = 0.037) and miR-373-3p (p = 0.005) were
higher in seminoma than in non-seminoma patients (Supplementary Figure S2A,B, Supplementary
Table S4), while miR-367-3p levels did not differ between both tumor types (Supplementary Figure S2C,
Supplementary Table S4). Analysis of cohort 1 and 2 combined confirmed significantly higher median
levels of miR-371a-3p (p = 0.016), miR-373-3p (p = 0.010) and miR-367-3p (p = 0.002) in the intermediate
risk group compared with the good risk group (Supplementary Table S5, Figure 3A–C). Median
levels of miR-371a-3p, miR-373-3p and miR-367-3p were not higher in patients from the poor risk
group compared to the good risk group (Supplementary Table S5, Figure 3A–C). Nonetheless, analysis
including non-seminoma patients only showed higher median miR levels of miR-373-3p (p = 0.030)
and miR-367-3p (p = 0.012) in poor prognosis compared to good prognosis patients (Supplementary
Table S6). Analysis of miR levels comparing different stages of disease showed that patients diagnosed
with stage III and IV had higher miR-367-3p levels (p = 0.007 and p = 0.004, respectively) than those
who had stage II disease (Supplementary Figure S2F, Supplementary Table S7). Levels of miR-371a-3p
and miR-373-3p did not statistically differ across the stages of disease (Supplementary Figure S2D,E,
Supplementary Table S7). From the 89 patients with evaluable LDH, AFP and β-HCG, nine (10.1%)
were negative for all three classical tumor markers. Interestingly, three of these nine patients were
positive for at least one of the miRs.
In patients from cohort 1 and 2 who underwent a postchemotherapy RPLND miR-371a-3p were
not elevated at time of the operation in the patients with fibrosis/necrosis or teratoma in their resected
lesions. In three of four patients who underwent a postchemotherapy RPLND, and found to have vital
tumor in their resected lesion, the miR 371a-3p was elevated.
Figure 2. Spearman correlation of relative levels of miR-371a-3p (A), miR-373-3p (B) and miR-367-3p
(C) and LHD before start of chemotherapy in cohort 1 and 2 combined (n = 101).
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Figure 3. Relative levels of miR-371a-3p (A), miR-373-3p (B) and miR-367-3p (C) before start of
chemotherapy in cohort 1 and 2 combined in good (n = 67), intermediate (n = 25) or poor risk (n = 17)
IGCCCG group. Relative levels of miR-371a-3p (D), miR-373-3p (E) and miR-367-3p (F) before start of
chemotherapy in cohort 1 and 2 with complete response (CR, n = 60), relapse (R, n = 34) or refractory
disease (RD, n = 15). The parameter p denotes Mann Whitney U test significance.
3.4. Use of miR Levels to Predict Relapse after a Complete Response, or Refractory Disease
The value of the miR levels before start of chemotherapy to predict relapse or refractory disease
was also evaluated. Analysis was performed using cohorts 1 and 2 combined (Figure 1) to enrich for
cases of relapse and refractory disease. Before start of chemotherapy, the median levels of miR-371a-3p
(p = 0.019), miR-373-3p (p = 0.036) and miR-367-3p (p ≤ 0.001) in patients with a durable complete
remission after chemotherapy were lower than the levels in patients who developed a relapse after
complete remission (Figure 3D–F, Supplementary Table S8). The median miR-367-3p level in patients
with refractory disease was higher than the level in patients who had a complete response (p = 0.022).
We also evaluated how many patients had elevated miR levels at time of diagnosis of relapse, or
refractory disease. From the total of 34 patients with relapse after complete remission, 21 had available
samples at moment of relapse. Twelve patients had at least one elevated miR when the relapse was
diagnosed. When using miR-371a-3p patients nine patients did not have elevated miR-371a-3p levels
at time of their relapse resulting in a sensitivity of 57%. Specificity could not be calculated based on
the defined selection of the patients within this cohort (absence of cases with elevated miR-371a-3p
without presence of a relapse). Details of these nine patients with a relapse after a biochemical complete
remission without an elevated miR-371a-3p level at time of the relapse are listed in Supplementary
Table S9. In seven patents elevated tumor markers (AFP in three, HCG in two, LDH in two) were
identified at the moment of relapse. In two patients, none of the biomarkers were elevated and both
had a retroperitoneal relapse. As indicated in Supplementary Table S9, two patients had only teratoma
at the relapsed site, explaining their negative miR-371a-3p level. In the two patients with seminoma
(and elevated LDH at time of relapse) no histology of the relapsed site was available. In five patients
histological examination of the relapsed site did contain other malignant components than teratoma
[embryonal carcinoma and yolk sac tumor].
Because the false positive elevated miR-371a-3p could not be estimated, the specificity was not
calculated. Eight of the patients with a relapse presented their relapse with elevated miRs earlier
than classical tumor markers, and in two other patients miRs were elevated, while the classical tumor
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markers remained negative. From thirteen out of fifteen patients with refractory disease, samples
during follow-up were available. Twelve of these patients (86.6%) had at least one elevated miR during
the follow-up period and in six patients elevated miR levels were observed, while classical tumor
markers were decreasing.
3.5. Kinetics of miR Levels during Chemotherapy in Cohort 1
Kinetics of miR levels were evaluated in patients from cohort 1 who had a miR level above
the previously described threshold [11]. Thirty-nine (58.2%) patients had levels above the threshold
of miR-371a-3p, nineteen (28.3%) of miR-373-3p and ten (14.9%) of miR-367-3p. Follow-up of miR
levels after initiation and during treatment showed a rapid decrease of miR-371a-3p, miR-373-3p
and miR-367-3p levels (Figure 4A–D). The sharp decrease after the initiation of the first cycle of BEP
administration was seen for all three miRs (Figure 4B–D). The miR levels fell below threshold in most
of the patients during the chemotherapy treatment.
Figure 4. Bleomycin, etoposide and cisplatin (BEP) containing chemotherapy schedule (3 or 4 courses)
as well as sampling time points (red arrows) of cohort 1 (A). Follow-up of relative level of miR-371a-3p
(n = 39) (B), miR-373-3p (n = 19) (C) and miR-367-3p (n = 10) (D) after start of chemotherapy. Patients
with relative miR levels above the described threshold at start of treatment are depicted. Repeated
measures ANOVA was used to test significance (* p < 0.05, ** p < 0.005).
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Analysis of the kinetics of miR levels during the first week upon treatment was used to estimate
half-life of miR-371-3p. Data were available from twelve patients belonging to cohort 1. This subset
of patients was selected upon positivity at start of chemotherapy, measurable miR levels at 24 and
eventually 48 h, and absence of later peaks of miR-371a-3p. The estimated median half-life of
miR-371-3p was 27 h (range 6–86 h).
3.6. The MiR Levels during Follow-up of Patients
Illustrative and representative cases of TGCC patients with metastatic disease who presented
with high levels of at least one of the miRs were studied individually after the start of chemotherapy
and during follow-up. Classical tumor markers, as well as miR levels from two patients (cases 1 and 2
from cohort 1) who had a complete response at last follow-up after BEP chemotherapy are outlined
in Figure 5. Patient depicted as case 1 (non-seminoma (embryonal carcinoma and teratoma), stage
II, intermediate IGCCCG risk group) had high levels of AFP and β-HCG at start of chemotherapy,
after which they normalized. Levels of miR-371a-3p and miR-373-3p followed the same pattern as
AFP and β-HCG, with high levels at the start of treatment and normalization after chemotherapy
(Figure 5A). Case 2 represents a patient diagnosed with stage 2 non-seminoma (embryonal carcinoma
and seminoma) who was negative for the classical tumor markers. Nevertheless, miR-371a-3p,
miR-373-3p and miR-367-3p levels were above the upper limit of normal and rapidly declined after
first BEP administration (Figure 5B). Supplementary Figure S3A shows levels of AFP and LDH of
case 3 (cohort 2): a patient who was diagnosed with mixed TGCC. At the moment of diagnosis, the
patient had stage 2 disease and was classified as intermediate risk according to the IGCCCG. The
patient underwent four cycles of BEP chemotherapy, after which AFP levels never normalized, and
was eventually diagnosed with refractory disease. Interestingly, levels of miR-371a-3p, miR-373-3p
and miR-367-3p dramatically increased at week 8, while AFP was slowly decreasing, pointing at the
early detection of this case of refractory disease only with the use of miRNA levels. Supplementary
Figure S3B represents case 4 (cohort 2); a seminoma patient (stage 2, good risk) with elevated LDH
only at moment of diagnosis who was treated with four courses of a carboplatin-based chemotherapy
regimen. Only miR-371a-3p and miR-367-3p were elevated at the start of treatment, and although
levels fluctuated, at week 26 all three miR levels increased drastically. A relapse was detected based on
CT scan at week 39, when the three miRs showed very high levels in contrast to the classical serum
bio-markers. Four courses of BEP chemotherapy were administered to the patient. During this second
line of chemotherapy, miR levels decreased but fluctuated around the normal threshold. The disease of
this patient ultimately progressed with a rise in all tumor markers and miR-371a-3p, miR-373-3p and
miR-367-3p levels followed this increase. Ultimately, the patient died of the disease.
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Figure 5. Levels of serum markers alpha-fetoprotein (AFP) (µg/L), LDH (UI/L) β-HCG (UI/mL) and
relative levels of miR-371a-3p, miR-373-3p and miR-367-3p at start of chemotherapy, during treatment
(red arrow) and follow-up of TGCC case 1 (A) and case 2 (B). Red arrows indicate chemotherapy
duration (three courses of BEP).
4. Discussion
This study indicates that serum levels of members of the miR-371 cluster and miR-367-3p before
start of chemotherapy correlate with various clinical features in metastatic TGCC patients, including
disease burden. TGCC patients belonging to the good IGCCCG prognosis group showed lower
median miR levels compared to the intermediate and poor risk groups. Patients who developed a
relapse after complete remission had higher levels of miR-371a-3p, miR-373-3p and miR-367-3p before
start of chemotherapy than patients who had a durable complete remission. Furthermore, median
level of miR-367-3p at the start was higher in metastatic patients who developed refractory disease.
Levels of miR-371a-3p, miR-373-3p and miR-367-3p decreased below threshold shortly after start of
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chemotherapy and after doing so those levels remained below threshold at one year after treatment
completion in the favorable responding patients.
Recent studies have confirmed the diagnostic value of miR-371a-3p, miR-373-3p and miR-367-3p
levels in germ cell tumors [10,11]. Patients with a TGCC had significantly higher miR-371a-3p,
miR-373-3p and miR-367-3p levels than healthy donors without cancer or patients with other
malignancies. Furthermore, two recent studies found that pre-chemotherapy miR levels were
associated with tumor stage [12,16]. Our data indicated that TGCC patients with stage III and IV had a
higher median level of miR-367-3p than stage II, but no differences in miR-371a-3p and miR-373-3p
levels. A limitation of our study is the absence of samples before orchiectomy, since the reduction in
tumor burden after surgery could influence miR levels. In the recent reported study of Dieckmann
et al. it was shown that detection of miR-371a-3p discriminates patients with localized disease from
those with metastases at the time of diagnosis with a sensitivity and specificity of 83.4% and 60.1%,
respectively [12]. The sensitivity of that study was higher than reported by us here, being at the time of
start of chemotherapy. It is known that orchiectomy results in a decrease in miR levels in many patients.
Of interest is that among the few clinical stage II patients [21.3%] in the Dieckmann et al. study the miR
level dropped to normal postoperatively (i.e., possible false negative finding). In our study, a much
higher percentage of patients (n = 66; 60.6%) had clinical stage II disease. Of these 35 patients (53.0%)
had a positive miR-371a-3p levels at start of chemotherapy. This might explain the lower percentage
(58.2%) of positive miR-371a-3p levels of the whole group at time of the start of chemotherapy. This is
in line with a previous study showing elevated miR-371a-3p levels in 51.7% of the cases [19]. It is a
tempting hypothesis that these miR-371a-3p patients are clinically over-staged. This is in line with
surgical studies documenting staging error in approximately 20% of clinical stage II patients [22].
Analysis of miR levels in relation with classical tumor markers showed that LDH positively
correlated with miR-371a-3p, miR-373-3p and miR-367-3p levels. LDH is regarded as an indirect
measure of tumor burden in TGCC patients [23]. This suggests that miR level can serve as an indirect
measure of tumor burden as well. In line with our findings, a recent report demonstrated that the
combined use of miR-371a-3p and miR-373-3p levels can identify the presence of vital tumor after
retroperitoneal lymph node dissection (RPLND) with a 100% sensitivity and 58% specificity [16].
In the current reported series, testicular cancer patients with only teratoma in their postchemotherapy
RPLND [n = 28] we did not find elevated miR 371a-3p levels at time resection of their residual disease
in line with previous studies [16].
Median miR levels before start of chemotherapy were higher in patients from the intermediate
and poor prognosis groups compared to good risk IGCCCG group. Nevertheless, it is not possible to
identify patients who are at higher risk of developing relapse or refractory disease since poor risk group
patients still have a 50% five-year overall survival. This means that there is a considerable proportion
of patients within this subset that will respond well to chemotherapy and have a favorable outcome [6].
Before start of chemotherapy, patients who developed a relapse after a complete biochemical response
had higher miR-371a-3p, miR-373-3p and miR-367-3p median levels than patients without relapse.
miR-367-3p was also higher in those who developed refractory disease. These data illustrate that
miR evaluation at start of chemotherapy will help to identify patients who are at higher risk of
developing relapse or refractory disease. Interestingly, 10% of relapse cases were detected with miR
levels in patients with negative classical tumor markers. In addition, in 40% of patients who developed
refractory disease miR levels were increasing while classical tumor markers were still decreasing.
The advantage of suspecting an unfavorable outcome before or earlier during treatment is to give
oncologists the possibility to adjust or intensify the chemotherapy treatment earlier in the course of the
disease in an effort to improve outcome. At time of a relapse after complete remission, 21 patients could
be evaluated. When using miR-371a-3p patients, nine patients did not have elevated miR-371a-3p
levels at time of their relapse resulting in a sensitivity of 57%. Two of these relapsed patients had only
teratoma at their relapsed site. These two patients had a negative miR level, as expected since teratoma
does not result in elevated serum miR-371a-3p level. Specificity could not be meaning-full estimated
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based on the low numbers and the defined selection of the patients within this particular cohort (i.e.,
absence of cases with elevated miR-371a-3p without presence of a relapse).
The levels of miR-371a-3p, miR-373-3p and miR-367-3p upon start of chemotherapy revealed a
rapid decrease during the first week of treatment. Furthermore, these levels remained below threshold
up to 1 year after chemotherapy completion. In line with our data, Dieckman and co-workers showed
that miR-371-3p levels were lower after the first cycle of chemotherapy compared to pre-chemotherapy
levels in patients with metastasis [12]. However, to our knowledge our study is the first that analyzed in
such detail the dynamics of miR-371a-3p, miR-373-3p and miR-367-3p levels during and after treatment
in a cohort of metastatic TGCC. Moreover, we gained insight in serum miR-371a-3p half-life after start
of BEP chemotherapy, which varied largely between patients and was estimated to be approximately
27 h.
In conclusion, we show miR-371a-3p, miR-373-3p and miR-367-3p to be potentially valuable
biomarkers in patients with metastatic TGCC. These miRs should be further evaluated before being
incorporated as part of clinical practice to identify patients with a higher risk of developing a relapse
after a complete biochemical response or who develop refractory disease. These miRs may have an
impact on the initial treatment of newly diagnosed TGCC patients with metastatic disease. The use of
these miRs could potentially identify TGCC patients with a worse prognosis. In addition, our results
demonstrate that miRs could be of value to follow-up TGCC patients who are negative for the classical
tumor markers.
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